Comparison of Corticotropin-Releasing Factor, Dexamethasone, and Temozolomide: Treatment Efficacy and Toxicity in U87 and C6 Intracranial Gliomas

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Cancer Research

• Publication date

  2011-03-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-10-3203PMID 21385926PMCID PMC3131845
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of bevacizumab on colon anastomotic healing in rats

  2010cited by this paper
• Corticotropin-releasing factor stimulation test.

  2010cited by this paper
• Antiangiogenic therapies for high-grade glioma

  2009cited by this paper
• Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

  2009influential reference
• Corticorelin acetate injections for the treatment of peritumoral brain edema

  2009cited by this paper
• Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

  2009influential reference
• A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral edema.

  2009cited by this paper
• Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

  2009cited by this paper
• Real-Time Imaging of HIF-1α Stabilization and Degradation

  2009cited by this paper
• A long-term open-label extension study examining the steroid-sparing effects of corticorelin acetate in patients with cerebral tumors.

  2009cited by this paper
• A randomized, double-blind study comparing corticorelin acetate with dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptoms of peritumoral brain edema.

  2009cited by this paper
• WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line.

  2008cited by this paper
• Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.

  2007cited by this paper
• Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.

  2007cited by this paper
• Corticorelin: ACTH RF, corticoliberin, corticotrophin-releasing hormone, corticotropin-releasing factor, human corticotropin-releasing hormone, ovine corticotrophin-releasing factor, Xerecept.

  2004cited by this paper
• Molecular Imaging of Temporal Dynamics and Spatial Heterogeneity of Hypoxia-Inducible Factor-1 Signal Transduction Activity in Tumors in Living Mice

  2004influential reference
• A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging

  2004cited by this paper
• A new role for corticotropin-releasing factor receptor-2: suppression of vascularization.

  2003cited by this paper
• Expression of CRF1 and CRF2 receptors in human cancers.

  2003cited by this paper
• CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway.

  2002influential reference
• Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs.

  2001influential reference
• Functional, endogenously expressed corticotropin‐releasing factor receptor type 1 (CRF1) and CRF1 receptor mRNA expression in human neuroblastoma SH‐SY5Y cells

  1999cited by this paper
• A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema.

  1998cited by this paper
• Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway.

  1998cited by this paper
• Corticotropin-releasing factor decreases vasogenic brain edema.

  1996cited by this paper
• RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma.

  1995cited by this paper
• Peripheral anti-inflammatory actions of corticotropin-releasing factor.

  1993cited by this paper
• CRF and Related Peptides as Anti‐Inflammatory Agonists a

  1993influential reference
• Anti-inflammatory peptide agonists.

  1993cited by this paper
• Epinephrine-induced pulmonary oedema in rats is inhibited by corticotropin-releasing factor.

  1992influential reference
• Corticotropin-releasing factor: an inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury.

  1991influential reference
• Corticotropin-releasing hormone.

  1988cited by this paper
• Acute neurologic dysfunction after high‐dose etoposide therapy for malignant glioma

  1988cited by this paper
• Anti-inflammatory activity of corticotropin releasing factor: I. Efficacy studies.

  1987influential reference
• Anti-inflammatory activity of corticotropin releasing factor: II. Mechanisms of action.

  1987cited by this paper
• The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome.

  1984cited by this paper
• Misonidazole increases the toxicity of BCNU for hypoxic cells.

  1982cited by this paper
• Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.

  1982cited by this paper
• Toxic Encephalopathy and Acute Brain‐swelling in Children

  1975cited by this paper
• SIDE-EFFECTS OF LONG-TERM TREATMENT WITH CORTICOSTEROIDS AND CORTICOTROPHIN.

  1964cited by this paper
• Oncotargets and Therapy Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress New Treatment Options in the Management of Glioblastoma Multiforme: a Focus on Bevacizumab

  year unknowncited by this paper

• Transnasal drug delivery to the brain: circumventing barriers for brain tumor patients.

  2025cites this paper
• Glioma and Peptidergic Systems: Oncogenic and Anticancer Peptides

  2024cites this paper
• Intracellular Acidification in a Rat C6 Glioma Model following Cariporide Injection Investigated by CEST-MRI

  2023cites this paper
• Combination toripalimab and bevacizumab for an elderly urothelial carcinoma patient with brain metastasis who failed rapidly after radiotherapy: a case report and literature review

  2022cites this paper
• Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies

  2022cites this paper
• Role of CRF and the hypothalamic‐pituitary‐adrenal axis in stroke: revisiting temporal considerations and targeting a new generation of therapeutics

  2022cites this paper
• Contemporary Mouse Models in Glioma Research

  2021cites this paper
• Structurally symmetric near-infrared fluorophore IRDye78-protein complex enables multimodal cancer imaging

  2021cites this paper
• Hallmarks of tumor-associated microglia response to experimental U87 human glioblastoma xenograft.

  2021cites this paper
• Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma

  2021cites this paper
• The Role of Urocortins in Intracerebral Hemorrhage

  2020cites this paper
• Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature.

  2019cites this paper
• Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group

  2018cites this paper
• Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.

  2018cites this paper
• Effects of dexamethasone on C6 cell proliferation, migration and invasion through the upregulation of AQP1

  2018cites this paper
• Human corticotrophin releasing factor inhibits cell proliferation and promotes apoptosis through upregulation of tumor protein p53 in human glioma

  2018cites this paper
• Apatinib in refractory radiation-induced brain edema

  2017cites this paper
• A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients

  2017cites this paper
• The effects of antiepileptic drugs on the growth of glioblastoma cell lines

  2016cites this paper
• The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells

  2016cites this paper
• The activation of type 1 corticotropin releasing factor receptor (CRF-R1) inhibits proliferation and promotes differentiation of neuroblastoma cells in vitro via p27(Kip1) protein up-regulation and c-Myc mRNA down-regulation.

  2015cites this paper
• Anti-tumor effects of progesterone in human glioblastoma multiforme: role of PI3K/Akt/mTOR signaling.

  2015cites this paper
• Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds.

  2014cites this paper
• Para- and Autocrine Mediators in the Glioma Microenvironment

  2014cites this paper
• NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer

  2013cites this paper
• Key role of CRF in the skin stress response system.

  2013cites this paper
• Development of therapeutics for high grade gliomas using orthotopic rodent models.

  2013cites this paper
• Corticosteroids effect on caspase 3 expression in an in-vitro model of hypoxic brain cells

  2013cites this paper
• Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?

  2013cites this paper
• Tumor-associated edema in brain cancer patients: pathogenesis and management

  2013cites this paper
• The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas

  2012cites this paper
• Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours.

  2012cites this paper
• Radionuclide-based reporter gene imaging: pre-clinical and clinical implementation and application

  2012cites this paper
• Animal models for glioma drug discovery

  2011cites this paper